Cargando…

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib

Crizotinib, which is effective in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, is sometimes associated with the generation of complex renal cysts. A 56-year-old man with ALK positive adenocarcinoma received crizotinib. Ten months after the introduction of crizo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taima, Kageaki, Tanaka, Hisashi, Tanaka, Yoshihito, Itoga, Masamichi, Takanashi, Shingo, Tasaka, Sadatomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635307/ https://www.ncbi.nlm.nih.gov/pubmed/28794366 http://dx.doi.org/10.2169/internalmedicine.8445-16

Ejemplares similares

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016)

Emergency Radiotherapy for Spinal Cord Compression due to Bone Sarcoidosis
por: Tanaka, Yoshihito, et al.
Publicado: (2017)

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Hisashi, et al.
Publicado: (2018)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
por: Shiratori, Toshihiro, et al.
Publicado: (2020)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2017)

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia
por: Tabe, Chiori, et al.
Publicado: (2022)

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series
por: Ishioka, Yoshiko, et al.
Publicado: (2022)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report
por: Baba, Keisuke, et al.
Publicado: (2019)

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus
por: Itoga, Masamichi, et al.
Publicado: (2015)

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study
por: Makiguchi, Tomonori, et al.
Publicado: (2023)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2021)

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2022)

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review
por: Tanaka, Hisashi, et al.
Publicado: (2013)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study
por: Fukushima, Takashi, et al.
Publicado: (2022)

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
por: Nakamura, Yume, et al.
Publicado: (2023)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
por: Pan, Yingying, et al.
Publicado: (2021)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib
por: Zhang, Chunzhi
Publicado: (2021)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
por: Jost, Tina, et al.
Publicado: (2022)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
por: Shen, Gang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1e5pjc02dvmur58quli92nm5aj